Skip to main content
. Author manuscript; available in PMC: 2021 Jan 1.
Published in final edited form as: Am J Transplant. 2019 Sep 26;20(1):250–261. doi: 10.1111/ajt.15581

Figure 2: Association Between GCSF use and Survival Among Propensity-Matched Cohort of Severely Neutropenic Patients.

Figure 2:

A) Severe neutropenia patients who received GCSF had significantly improved overall survival than those who did not (aHR for death 0.24, 95% CI 0.07–0.88, p=0.031). B) Severe neutropenia patients who received GCSF had significantly improved post-neutropenia survival than severe neutropenia patients who did not (aHR for death 0.17, 95% CI 0.04–0.63, p=0.008).